Home / Business and Economy / Biotech Scribe Aims for $107M IPO
Biotech Scribe Aims for $107M IPO
20 Jul
Summary
- Scribe Therapeutics plans to raise up to $107.2 million.
- The company is developing gene therapies for heart conditions.
- Eli Lilly & Co. is among the firm's notable backers.
Scribe Therapeutics Inc., a clinical-stage biotechnology firm focused on developing gene therapies for heart diseases, is embarking on a substantial fundraising initiative. The company is actively seeking to secure up to $107.2 million through an initial public offering (IPO) in the United States.
Headquartered in Alameda, California, Scribe Therapeutics has garnered support from notable entities, including Eli Lilly & Co. The firm intends to offer 7.2 million shares of its stock to the public as part of this IPO, signaling a significant step in its growth and development strategy.
This IPO represents a crucial opportunity for Scribe Therapeutics to acquire the necessary capital to further its research and development pipeline. The company's work is centered on creating novel gene-based treatments aimed at addressing various heart conditions, a major area of unmet medical need.
